For the quarter ending 2026-03-31, RSMDF had $243,444K increase in cash & cash equivalents over the period. $520,478K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 398,732 | 392,593 | 348,536 | 379,705 |
| Depreciation and amortization | 58,981 | 49,885 | 47,698 | 63,628 |
| Amortization of right-of-use assets | 10,051 | 12,445 | 9,971 | 10,660 |
| Stock-based compensation costs | 26,792 | 28,938 | 21,160 | 24,751 |
| (gain) loss attributable to equity method investments, net of dividends received (note 6) | - | - | - | 3,644 |
| (gain) loss attributable to equity method investments (note 5) | 2,309 | 506 | 1,907 | - |
| (gain) loss on equity investments (note 5) | -10,130 | 306 | -6,190 | -2,534 |
| Restructuring expenses (note 17) | - | - | - | 0 |
| Gain on insurance recoveries | - | - | - | 0 |
| Accounts receivable | 16,857 | 72,682 | -29,970 | 5,215 |
| Inventories | -12,480 | -26,129 | 14,663 | 32,133 |
| Prepaid expenses, net deferred income taxes and other current assets | 48,335 | 106,387 | -2,312 | -47,017 |
| Accounts payable, accrued expenses, income taxes payable and other | 103,876 | 10,645 | 7,636 | 49,088 |
| Net cash provided by (used in) operating activities | 554,132 | 339,745 | 457,321 | 538,766 |
| Purchases of property, plant and equipment | 33,654 | 28,539 | 42,965 | 30,585 |
| Patent registration and acquisition costs | 5,935 | 7,351 | - | - |
| Purchases of intangible assets | 0 | -1,335 | 2,814 | 3,193 |
| Business acquisitions, net of cash acquired | 24,883 | 0 | 522 | 138,578 |
| Purchases of investments (note 5) | 20,132 | 4,231 | 2,173 | 2,013 |
| Proceeds from exits of investments (note 5) | 2,502 | 250 | 0 | 250 |
| Proceeds (payments) on maturity of foreign currency contracts | -24,074 | 12,406 | 4,104 | -40,406 |
| Net cash provided by (used in) investing activities | -58,028 | -50,942 | -52,578 | -133,713 |
| Proceeds from issuance of common stock, net | 7,427 | 29,557 | 8,205 | 30,156 |
| Taxes paid related to net share settlement of equity awards | 418 | 20,308 | 719 | 590 |
| Purchases of treasury stock | 175,013 | 175,014 | 150,010 | 100,008 |
| Payments of business combination contingent consideration | 0 | 0 | 0 | 0 |
| Acquisition of consolidated subsidiary | - | - | - | 10,855 |
| Proceeds from borrowings, net of borrowing costs | - | - | - | 0 |
| Repayment of borrowings | 0 | 5,000 | 0 | 5,000 |
| Dividends paid | 87,238 | 87,584 | 87,750 | 77,590 |
| Net cash provided by (used in) financing activities | -255,242 | -258,349 | -230,274 | -163,887 |
| Effect of exchange rate changes on cash | 2,582 | 2,767 | -71 | 35,573 |
| Net increase (decrease) in cash and cash equivalents | 243,444 | 33,221 | 174,398 | 276,739 |
| Cash and cash equivalents at beginning of period | 1,417,069 | 1,383,848 | 1,209,450 | 932,711 |
| Cash and cash equivalents at end of period | 1,660,513 | 1,417,069 | 1,383,848 | 1,209,450 |
RESMED INC (RSMDF)
RESMED INC (RSMDF)